Investors

Half year liquidity contract statement

15 January 2021, Sophia Antipolis, France

Press Release – For immediate release – 05:45 pm CET

Half year liquidity contract statement

Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to Louis Capital Markets|Midcap Partners, the following resources were listed in the liquidity account as of 12/31/2020:

  • 35,698 shares
  • € 79,709.31 in cash

During the second half of 2020, it has been traded a total of:

BUY 180,188 Shares EUR 1,271,243.68 540 transactions
SELL 177,008 Shares EUR 1,276,566.46 461 transactions

It is recalled that at the time of the half-yearly statement of 06/30/2020, the following resources were included in the liquidity account:

  • 32,518 shares
  • € 77,124.37 in cash

It is recalled that when the new liquidity contract was put in place on 05/04/2020, the following resources were made available:

  • 4,404 shares
  • € 173,829.64 in cash

The daily transaction table is provided in the appendix to this press release.

In addition, please note that in connection with the acquisition of Louis Capital Markets|Midcap Partners by the TPICAP Plc group, the liquidity agreement previously held by Louis Capital Markets UK, LLP was automatically transferred on 12/31/2020 to TP ICAP (EUROPE), the French entity of the TPICAP group, authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com

Contacts

Median Technologies

Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Actifin  (Investors)

Ghislaine Gasparetto
+33 6 21 10 49 24
ggasparetto@actifin.fr

Alizé RP  (Press)

Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com